FNAM (Evolutionary Genomics) Research & Development: $0.42 Mil (TTM As of Dec. 2022)


FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics Research & Development?

Evolutionary Genomics FNAM 31 Research & Development is $0.42 Mil as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Research & Development is the aggregate amount of research and development expenses during the year. Evolutionary Genomics's Research & Development for the three months ended in Dec. 2022 was $0.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 was $0.42 Mil.

Evolutionary Genomics  (OTCPK:FNAM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Evolutionary Genomics Research & Development Related Terms

Evolutionary Genomics Research & Development Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Research & Development Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.47 1.79 1.23 0.42

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.10 0.11 0.12 0.09
FNAM
31GF Score
Evolutionary Genomics Inc FNAM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.42 Mil mean?
Evolutionary Genomics (FNAM) has a Research & Development of $0.42 Mil as of Dec. 2022. Research and development expense is the total cost for research and development activities. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Research & Development too high?
Evolutionary Genomics' current Research & Development is $0.42 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Research & Development compare to BXRX and GNCA?
Evolutionary Genomics' Research & Development of $0.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current Research & Development is $0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Research & Development of $0.42 Mil. The current Research & Development is $0.42 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Research & Development is $0.42 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price